Nephrology Dialysis Transplantation

Identifying critically important vascular access outcomes for trials in haemodialysis: An international survey with patients, caregivers and health professionals.  35:657-668. 2020

Serum albumin concentration and risk of end-stage renal disease: The REGARDS study.  33:1770-1777. 2018

Association of serum albumin levels with kidney function decline and incident chronic kidney disease in elders.  33:986-992. 2018

Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: A systematic review and individual patient data meta-analysis.  33:1017-1024. 2018

Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis.  32:2079-2089. 2017

Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.  32:1493-1503. 2017

The pressing need for real-time risk assessment of hospital-acquired acute kidney injury.  32:766-770. 2017

Competing risks: you only die once.  31:1033-1035. 2016

Connecting the dots on fibroblast growth factor 23 and left ventricular hypertrophy.  31:1031-1033. 2016

Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.  31:1088-1099. 2016

Fibroblast growth factor 23 and heart failure: The plot thickens.  31:688-690. 2016

APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.  31:602-608. 2016

N-Acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy.  30:234-238. 2015

Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.  29:2028-2035. 2014

The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: Subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.  29:1203-1210. 2014

Comparison of absolute serum creatinine changes versus Kidney Disease: Improving Global Outcomes consensus definitions for characterizing stages of acute kidney injury.  28:1447-1454. 2013

Experimental evidence of cell dissemination playing a role in pathogenesis of IgA nephropathy in multiple lymphoid organs.  28:320-326. 2013

Expression of fgf23 and αklotho in developing embryonic tissues and adult kidney of the zebrafish, Danio rerio.  27:4314-4322. 2012

Chronic renal denervation increases renal tubular response to P2X receptor agonists in rats: Implication for renal sympathetic nerve ablation.  27:3443-3448. 2012

Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease.  27:3482-3488. 2012

Solute clearance in CRRT: Prescribed dose versus actual delivered dose.  27:952-956. 2012

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation..  27:1042-1049. 2012

Incidence of stroke symptoms among adults with chronic kidney disease: Results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.  27:166-173. 2012

Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment..  27:1729-1736. 2012

Renal outcomes of agalsidase beta treatment for Fabry disease: Role of proteinuria and timing of treatment initiation.  27:1042-1049. 2012

Variability in urinary oxalate measurements between six international laboratories.  26:3954-3959. 2011

IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells.  26:3451-3457. 2011

Role of lean body mass in estimating glomerular filtration rate in Alzheimer disease.  26:2222-2231. 2011

Severe venous neointimal hyperplasia prior to dialysis access surgery.  26:2264-2270. 2011

Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort.  26:1258-1265. 2011

Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.  26:584-591. 2011

Race differences in prevalence of chronic kidney disease among young adults using creatinine-based glomerular filtration rate-estimating equations.  25:3934-3939. 2010

Racial differences in postprandial mineral ion handling in health and in chronic kidney disease.  25:3970-3977. 2010

A case of infection-associated antiproteinase-3-negative cytoplasmic antineutrophil cytoplasmic antibody pauci-immune focal necrotizing glomerulonephritis.  25:3119-3123. 2010

Glomerulonephritis after hematopoietic cell transplantation: IgA nephropathy with increased excretion of galactose-deficient IgA1.  25:1708-1713. 2010

End-stage renal disease in patients with Fabry disease: Natural history data from the Fabry Registry.  25:769-775. 2010

Tissue distribution and biological activities of immune complexes are determined by their size and composition.  25:1007. 2010

Acute kidney injury: Where's the consensus about its definition.  25:9-11. 2010

Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN).  25:2168-2177. 2010

Who should be referred for a fistula? A survey of nephrologists.  25:2644-2651. 2010

Exploration of anaemia as a progression factor in African Americans with cardiovascular disease.  24:3404-3411. 2009

A comparison of observed versus estimated baseline creatinine for determination of RIFLE class in patients with acute kidney injury.  24:2739-2744. 2009

Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.  24:2102-2111. 2009

Nephropathy in Fabry disease: The importance of early diagnosis and testing in high-risk populations.  24:1736-1743. 2009

Association of chronic kidney disease with outcomes in chronic heart failure: A propensity-matched study.  24:186-193. 2009

IgA Nephropathy in children and adults: Comparison of histologic features and clinical outcomes.  23:2537-2545. 2008

Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy.  23:1600-1607. 2008

Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.  22:1593-1600. 2007

Haem oxygenase-1 - A culprit in vascular and renal damage?.  22:1495-1499. 2007

Genome scan of glomerular filtration rate and albuminuria: The HyperGEN study.  22:763-771. 2007

Arteriovenous access outcomes in haemodialysis patients with HIV infection.  22:465-470. 2007

Catheter-related bacteraemia in haemodialysis patients with HIV infection.  21:3185-3188. 2006

IgA-containing immune complexes in the urine of IgA nephropathy patients.  21:2478-2484. 2006

Glyoxylate reductase activity in blood mononuclear cells and the diagnosis of primary hyperoxaluria type 2.  21:2292-2295. 2006

Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats.  20:1573-1581. 2005

Racial disparities in the association of foetal growth retardation to childhood blood pressure.  20:1592-1597. 2005

Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil.  20:1214-1221. 2005

The spectrum of infection-related morbidity in hospitalized haemodialysis patients.  20:1180-1186. 2005

AL-amyloidosis is underdiagnosed in renal biopsies.  19:3050-3053. 2004

Association of pelvic arterial calcification with arteriovenous thigh graft failure in haemodialysis patients.  19:2564-2569. 2004

Sodium ferric gluconate complex in haemodialysis patients: A prospective evaluation of long-term safety.  19:1576-1580. 2004

Treatment of catheter-related bacteraemia with an antibiotic lock protocol: Effect of bacterial pathogen.  19:1237-1244. 2004

Galectin-3-positive cell infiltration in human diabetic nephropathy.  19:602-607. 2004

WNK kinases, distal tubular ion handling and hypertension.  18:2463-2467. 2003

Novel concepts in understanding and management of glomerular proteinuria.  17:951-955. 2002

Protease inhibitor therapy for HIV infection: The effect on HIV-associated nephrotic syndrome.  14:744-747. 1999

Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit [6].  13:2979-2980. 1998

Immunological studies of IgA nephropathy in blacks reveal elevations of serum IgA2 as well as IgA1.  9:1324-1329. 1994

Genetic factors in primary IgA nephropathy.  2:134-142. 1987